IndustryCompany release

Neuronetics investor deck reports $149.2M 2025 revenue and over 261,000 NeuroStar patients

🇺🇸 Neuronetics, Inc. (STIM) · Wed 04 Nov 2026

The US maker of the NeuroStar TMS system cites revenue and patient figures in an investor presentation that also flags going-concern and credit facility risks.

Neuronetics, the US company behind the NeuroStar Advanced Therapy System for depression that has not responded to antidepressants, has filed an investor presentation citing revenue of $149.2 million for 2025.

The deck also puts the number of unique patients treated with NeuroStar at about 261,591, and the number of treatments delivered at 9.45 million, both as of 30 September 2026. It additionally describes the company's Greenbrook TMS clinic network.

On risk, the presentation refers to going-concern and credit facility concerns. It also states that psychedelic therapies would still need FDA approval, a point the company raises in discussing the competitive landscape for depression treatment.

The full text of the presentation was not available for this report, so further detail on the financial position, the terms of the credit facility or the clinic network cannot be given here.

What it means for your team

  • Market-access teams tracking neuromodulation can note the stated scale of NeuroStar use: roughly 261,591 patients and 9.45 million treatments to 30 September 2026.
  • The going-concern and credit facility references are risk disclosures worth monitoring for anyone assessing supplier or provider stability.
  • The company's statement that psychedelic therapies still need FDA approval frames them as potential future alternatives rather than current options.

Company's press release (SEC filing): Neuronetics, Inc. ↗

Article written by VigiEye from the official source (Neuronetics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →